Publication details

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry

Authors

KOCÁKOVÁ Ilona MELICHAR Bohuslav KOCÁK Ivo BORTLÍČEK Zbyněk BÜCHLER Tomáš DUŠEK Ladislav PETRUŽELKA Luboš KOHOUTEK Milan PRAUSOVÁ Jana FÍNEK Jindřich MOHELNIKOVA-DUCHONOVA Beatrice VYZULA Rostislav

Year of publication 2015
Type Article in Periodical
Magazine / Source Anticancer Research
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Bevacizumab; FOLFIRI; XELIRI; colorectal cancer
Description Aim: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). Patients and Methods: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). Results: Among 4,312 patients with CRC treated with bevacizumab, only 13% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. Conclusion: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.

You are running an old browser version. We recommend updating your browser to its latest version.

More info